J Gomes1, F Au1,2, A Basak1, S Cakmak2, R Vincent2,3, P Kumarathasan1,2,4. 1. Faculty of Health Science, Interdisciplinary School of Health Sciences, Ottawa, Canada. 2. Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, Canada. 3. Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada. 4. Analytical Biochemistry and Proteomics Laboratory, Mechanistic Studies Division, Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Ottawa, Canada.
Abstract
Background: Pregnancy is a vulnerable period for the mother and the infant and exposures to environmental chemicals in utero can influence neonatal morbidity and mortality. There is a momentum toward understanding and exploring the current maternal biological mechanisms specific to in utero effects, to improve birth outcomes. This study aims to examine the current understanding of the role of biomarkers that may be associated with term of pregnancy, infant birth weights and infant development in utero. Methods: Electronic searches were conducted in PubMed, Embase, OvidMD, and Scopus databases; and all relevant research articles in English were retrieved. Studies were selected if they evaluated maternal blood plasma/serum biomarkers proposed to influence adverse birth outcomes in the neonate. Data were extracted on characteristics, quality, and odds ratios from each study and meta-analysis was conducted. Results: A total of 54 studies (35 for meta-analysis), including 43,702 women, 50 plasma markers and six descriptors of birth outcomes were included in the present study. The random effect point estimates for risk of adverse birth outcomes were 1.61(95%CI: 1.39-1.85, p < 0.0001) for inflammation-related biomarkers and 1.65(95%CI: 1.22-2.25, p = 0.0013) for growth factor/hormone-related biomarkers. All subgroups of plasma markers showed significant associations with adverse birth outcomes with no apparent study bias.Conclusions: The two subsets of plasma markers identified in this study (inflammation-related and growth factor/hormone-related) may serve as potentially valuable tools in the investigation of maternal molecular mechanisms, especially select pathways underlying inflammatory and immunological mediation in terms of modulating adverse infant outcomes. Future large, prospective cohort studies are needed to validate the promising plasma biomarkers, and to examine other maternal biological matrices such as cervicovaginal fluid and urine.
Background: Pregnancy is a vulnerable period for the mother and the infant and exposures to environmental chemicals in utero can influence neonatal morbidity and mortality. There is a momentum toward understanding and exploring the current maternal biological mechanisms specific to in utero effects, to improve birth outcomes. This study aims to examine the current understanding of the role of biomarkers that may be associated with term of pregnancy, infant birth weights and infant development in utero. Methods: Electronic searches were conducted in PubMed, Embase, OvidMD, and Scopus databases; and all relevant research articles in English were retrieved. Studies were selected if they evaluated maternal blood plasma/serum biomarkers proposed to influence adverse birth outcomes in the neonate. Data were extracted on characteristics, quality, and odds ratios from each study and meta-analysis was conducted. Results: A total of 54 studies (35 for meta-analysis), including 43,702 women, 50 plasma markers and six descriptors of birth outcomes were included in the present study. The random effect point estimates for risk of adverse birth outcomes were 1.61(95%CI: 1.39-1.85, p < 0.0001) for inflammation-related biomarkers and 1.65(95%CI: 1.22-2.25, p = 0.0013) for growth factor/hormone-related biomarkers. All subgroups of plasma markers showed significant associations with adverse birth outcomes with no apparent study bias.Conclusions: The two subsets of plasma markers identified in this study (inflammation-related and growth factor/hormone-related) may serve as potentially valuable tools in the investigation of maternal molecular mechanisms, especially select pathways underlying inflammatory and immunological mediation in terms of modulating adverse infant outcomes. Future large, prospective cohort studies are needed to validate the promising plasma biomarkers, and to examine other maternal biological matrices such as cervicovaginal fluid and urine.
Authors: Shannon L Gillespie; Lisa M Christian; Amy R Mackos; Timiya S Nolan; Kaboni W Gondwe; Cindy M Anderson; Mark W Hall; Karen Patricia Williams; George M Slavich Journal: Brain Behav Immun Date: 2022-01-11 Impact factor: 19.227
Authors: Priyanka Gogna; Will D King; Paul J Villeneuve; Premkumari Kumarathasan; Markey Johnson; Bruce Lanphear; Robin H Shutt; Tye E Arbuckle; Michael M Borghese Journal: Environ Epidemiol Date: 2021-09-07
Authors: Miguel A Ortega; Oscar Fraile-Martínez; Cielo García-Montero; Miguel A Sáez; Miguel Angel Álvarez-Mon; Diego Torres-Carranza; Melchor Álvarez-Mon; Julia Bujan; Natalio García-Honduvilla; Coral Bravo; Luis G Guijarro; Juan A De León-Luis Journal: Cells Date: 2022-02-06 Impact factor: 6.600
Authors: Emily S Miller; George R Saade; Hyagriv N Simhan; Catherine Monk; David M Haas; Robert M Silver; Brian M Mercer; Samuel Parry; Deborah A Wing; Uma M Reddy; William A Grobman Journal: Am J Obstet Gynecol Date: 2021-07-17 Impact factor: 8.661